Why Farbe Firma is the Top Manufacturer of Labetalol HCL Injection
- Maulik Sudani
- May 24
- 6 min read
Last Updated: May 24, 2026
TL;DR: Labetalol HCL Injection — labetalol hydrochloride, a combined alpha-1 and non-selective beta-adrenergic receptor blocker supplied as a clear sterile aqueous solution in ampoules and vials — is the intravenous antihypertensive clinicians rely on to bring dangerously high blood pressure under rapid, controlled command in hypertensive emergencies, in severe hypertension of pregnancy and pre-eclampsia, and in perioperative and postoperative blood-pressure spikes. Farbe Firma Pvt Ltd manufactures WHO-GMP certified Labetalol HCL Injection at our Gujarat, India facility and supplies it to hospital tenders, obstetric and critical-care programmes, distributors and brand owners in 30+ countries.
Key Takeaways
Drug class: Combined alpha-1 and non-selective beta-adrenergic receptor antagonist — a parenteral antihypertensive that lowers blood pressure smoothly without the reflex tachycardia of pure vasodilators, used for hypertensive emergencies and urgencies, severe hypertension in pregnancy and pre-eclampsia, and perioperative and postoperative hypertension. A first-line obstetric antihypertensive and a routine critical-care item.
Certified manufacturing: WHO-GMP certified plant, ISO Class 5 aseptic core, validated water-for-injection loops, qualified ampoule and vial filling lines with nitrogen purging and tight acidic pH control, and validated terminal moist-heat sterilisation with full container-closure integrity verification.
CTD-ACTD dossier support: Full eCTD and ACTD modules, ICH Q1A long-term and accelerated stability data, ICH Q1B photostability data, drug master files and CEP-style documentation for registrations across regulated and emerging markets.
End-to-end CMO services: Contract manufacturing, third-party manufacturing, private-label artwork, multilingual leaflets, tender-ready packaging and logistics coordination for buyers in Africa, LATAM, CIS, GCC, MENA and Southeast Asia.
Introduction: Why Labetalol HCL Injection Demands a Premium Manufacturer
Labetalol HCL Injection earns its place in the emergency-medicine and obstetric toolkit because it does something few antihypertensives do well: it lowers a dangerously elevated blood pressure quickly, predictably and smoothly. By blocking alpha-1 receptors it relaxes vascular tone, and by blocking beta receptors it prevents the reflex tachycardia that would otherwise follow — so the heart is not driven harder while the pressure falls. That dual action makes it the drug of choice when a clinician must take control of a hypertensive emergency without overshooting, and it is why labetalol is a recommended option for severe hypertension in pregnancy and pre-eclampsia, where both maternal and foetal safety hinge on a controlled descent rather than a crash.
That clinical role places exacting demands on the manufacturer. Labetalol HCL Injection is given by slow intravenous injection or by titrated infusion, commonly as a 5 mg/mL solution in 4 mL (20 mg) and 20 mL (100 mg) presentations, so every container must deliver an accurate, uniform dose that a clinician can trust while titrating against a falling blood pressure. The active is formulated as an acidic aqueous solution because labetalol hydrochloride is most stable at low pH, and that stability window has to be held precisely: drift toward neutral pH, excess dissolved oxygen, or an over-long warm hold during processing all erode the molecule. Choosing a Labetalol HCL Injection manufacturer that treats pH control, dose uniformity and container-closure integrity as core engineering disciplines — not afterthoughts — is what keeps an emergency antihypertensive supply chain dependable.
What Sets a World-Class Labetalol HCL Injection Manufacturer Apart
A world-class manufacturer of Labetalol HCL Injection invests in three areas that weaker suppliers underfund: precision aqueous formulation, oxidation- and pH-controlled processing, and a stability programme built for real-world tropical distribution. Precision formulation means validated dissolution of the active into large water-for-injection batches, in-process assay at multiple points, controlled fill-volume checks across the entire run, and content-uniformity verification so that the first and the last container of a batch carry the same accurate dose. For a drug titrated against a patient's blood pressure minute by minute, that consistency is not a quality nicety — it is the foundation of safe dosing.
Oxidation- and pH-controlled processing matters because labetalol's stability is conditional. World-class plants compound the bulk solution under nitrogen blanket to limit oxidation, adjust and verify pH within the narrow acidic band where labetalol hydrochloride is most stable, minimise the time the bulk spends warm, and validate the terminal moist-heat sterilisation cycle so the lethality delivered to microorganisms does not come at the cost of unacceptable drug degradation. ICH Q1B photostability testing confirms the chosen ampoule, vial and carton protect the product across its shelf life. All of this is documented cleanly for audit, supported by electronic batch records that lock deviations the moment they occur, and reinforced by 100% container leak and integrity inspection from filling through final packaging.
Quality Systems Behind Every Labetalol HCL Injection
Every Farbe Firma Labetalol HCL Injection batch is released only after a full stack of quality checks: identity and assay by validated stability-indicating HPLC against USP, BP, IP or EP reference standards, related-substances profiling to confirm degradation products stay within monograph limits, pH, particulate matter, bacterial endotoxin by LAL, sterility by membrane filtration, and content-uniformity testing appropriate to a titratable parenteral. Certificates of analysis are issued with full traceability back to API lot, excipient lot, primary-packaging lot and the qualified person responsible for release.
Around those release tests sits a deeper quality architecture: validated water-for-injection generation and looped distribution, qualified HVAC with continuous environmental monitoring, calibrated sterilisation and depyrogenation equipment, validated terminal moist-heat cycles with load mapping, and an electronic batch record system tied into our deviation, change-control and CAPA workflows. Stability is tracked under both long-term (30 °C / 65 % RH) and accelerated (40 °C / 75 % RH) ICH Q1A conditions — Zone IVb included — so we can assure customers the Labetalol HCL Injection they buy today will still meet specification when it reaches the patient months later in any climate.
Looking for a sterile injectable manufacturing partner? Submit a Quick Inquiry
Why Farbe Firma is the Trusted Labetalol HCL Injection Manufacturer for Global Buyers
Farbe Firma Pvt Ltd manufactures more than 100 sterile injectables across cardiovascular, emergency-medicine, obstetric, anaesthesia and critical-care categories. For Labetalol HCL Injection specifically, we supply the 5 mg/mL strength in 4 mL (20 mg) ampoule and 20 mL (100 mg) vial presentations as standard, with custom strengths, fill volumes and pack configurations available under contract manufacturing agreements. Every batch is released to WHO-GMP standards, with the underlying CTD or ACTD dossier ready to hand for registration in the buyer's target market.
Our CDMO services scale cleanly from hospital pharmacy supply to full national tender procurement. We prepare full eCTD and ACTD modules, drug master files, ICH Q1A and Q1B stability packages, translated package inserts and artwork for Spanish, French, Portuguese, Russian and Arabic markets, and coordinate shipping and logistics to the destination. When a buyer needs Labetalol HCL Injection on a tight deadline — and antihypertensive stock for obstetric and emergency units often is urgent — our regulatory, manufacturing and logistics teams move as one: dossier, artwork, production slot and shipment plan delivered as a single coordinated package, with a single accountable point of contact.
Buyers stay with Farbe Firma because of audit-readiness and communication. Customer auditors are welcomed onto the plant floor; our quality unit answers technical queries with primary data, not slogans; and our reviewer team — practising pharmacists and R&D scientists — can talk through formulation, pH control, sterilisation strategy, container-closure and stability choices in real detail. For an emergency antihypertensive where dose accuracy and sterility decide patient outcomes, that openness is exactly what global buyers tell us they value most.
Explore Farbe Firma: Products | Global Reach | About Us
Frequently Asked Questions (FAQ)
Is Farbe Firma a WHO-GMP certified Labetalol HCL Injection manufacturer?
Yes. Farbe Firma Pvt Ltd holds WHO-GMP certification and manufactures Labetalol HCL Injection at a Gujarat, India facility with ISO Class 5 aseptic processing, qualified ampoule and vial filling lines, qualified water-for-injection systems and validated environmental monitoring. WHO-GMP, USP, BP, IP and EP compliance documentation is available on request.
Which strengths and pack sizes of Labetalol HCL Injection do you supply?
Our standard presentation is labetalol hydrochloride 5 mg/mL as a clear sterile solution in 4 mL (20 mg) ampoules and 20 mL (100 mg) vials for slow intravenous injection or infusion. Custom strengths, fill volumes, ampoule and vial formats and country-specific pack configurations are available under contract manufacturing agreements — share your specification and our technical team will quote within 48 hours.
Can Farbe Firma support country-specific registrations for Labetalol HCL Injection?
Yes. We provide full CTD and ACTD dossier modules, drug master files, ICH Q1A stability packages (long-term and accelerated), ICH Q1B photostability data, and translated package inserts and artwork for Spanish, French, Portuguese, Russian and Arabic markets. Our regulatory team has supported registrations across 30+ countries in Africa, LATAM, CIS, GCC, MENA and Southeast Asia.
How does Farbe Firma protect Labetalol HCL Injection stability during manufacturing?
Labetalol hydrochloride is most stable as an acidic aqueous solution, so the bulk is compounded under nitrogen blanket, the pH is adjusted and verified within labetalol's narrow acidic stability window, and the terminal moist-heat sterilisation cycle is validated against a defined degradation budget. Degradation products are monitored on every batch by validated stability-indicating HPLC against monograph limits, and ICH Q1B photostability data confirm the container and carton protect the product.
What is the minimum order quantity for Labetalol HCL Injection contract manufacturing?
MOQs vary by strength, label complexity and dossier requirements. For the standard 5 mg/mL ampoule and vial presentations we accommodate hospital-scale and full-tender-scale orders. Contact director@farbefirma.org for a specific quotation against your specification.
Technically Reviewed By: Maulik Sudani | Jignasu Sudani (Technical Expert)
Website: www.farbefirma.org | Email: director@farbefirma.org | Address: Gujarat, INDIA
Request a Quote | View Products | FAQ | Blog
Comments